Navigation Links
Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial
Date:9/1/2010

were held across 90 centers in 7 countries.

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin has completed two Phase III clinical trials for the non-surgical treatment of retinal disorders. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal conditions. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (anti-Factor VIII), a long acting anti-coagulant in Phase II, and TB-403 (anti-PlGF) in Phase Ib/II for cancer in partnership with Roche.

ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

For further information please contact: ThromboGenics Dr. Steve Pakola, CMO Tel: +1(212)201-0920 steve.pakola@thrombogenics.com
'/>"/>

SOURCE ThromboGenics NV
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology
2. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
3. Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival
4. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
5. SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia
6. Xceed Meets HTX/CIHR Grant Milestone: Decreasing Sample-Prep Time From Days to Less Than Eight Hours
7. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
8. Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria
9. Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria
10. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
11. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... light, rather than electricity, to move data would ... is a growing concern as chips, transistor counts ... optical circuits light emitters, modulators, and detectors ... promising light source for optical chips is molybdenum ... deposited as a single, atom-thick layer. Other experimental ...
(Date:9/19/2014)... SAN FRANCISCO , Sept. 19, 2014 /PRNewswire/ ... announced results from preclinical studies characterizing the analgesic ... oral, peripherally-acting kappa opioid receptor agonist molecules. The ... molecule polymer medicinal chemistry platform. The ... described in the medical literature. 1,2 Kappa ...
(Date:9/19/2014)... 2014 Cereal grain scientists, quality ... gather October 5–8, 2014, for the AACC International ... Center in Providence, Rhode Island. The comprehensive scientific ... food scientists, chemists, microbiologists, nutritionists, and those interested ... management. To date, 1,000 attendees have registered for ...
(Date:9/18/2014)... 18, 2014 Bipartisan passage this week ... designed to stimulate development and commercialization of new technologies ... by leaders of SPIE, the international society for ... Manufacturing and Innovation (RAMI) Act, now moves to the ... said they are optimistic that it will win passage ...
Breaking Biology Technology:Toward optical chips 2Toward optical chips 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 3House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 2House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 3
... 27, 2012 Medstreaming, a leading provider of medical ... module for its All in One EMR/PACS/Practice Management platform ... Web-Based Analytic-Based EMR/PACS platform will enable Medstreaming EMR customers ... imaging data in any format, including DICOM. ...
... Minn., Feb. 27, 2012  Nausea and vomiting in pregnancy (NVP) ... estimated 70 to 85% of all pregnant women.(1) Yet in ... (NPs), only 40% of their patients reported experiencing NVP in ... patient and healthcare provider dialogue about the condition.    ...
... Jyvskyl, Finland, and at Harvard University, US, have discovered a ... have been able to predict that long and narrow graphene ... twisting. The research has received funding from the Academy of ... just twist the ends of a strap on your backpack ...
Cached Biology Technology:Medstreaming Launches Web-Based Analytics for All in One EMR/PACS/Practice Management Platform at HIMSS 2Medstreaming Launches Web-Based Analytics for All in One EMR/PACS/Practice Management Platform at HIMSS 3Morning Sickness or NVP: National Survey of Nurse Practitioners Points to Underreporting of Common Condition in Pregnancy 2Morning Sickness or NVP: National Survey of Nurse Practitioners Points to Underreporting of Common Condition in Pregnancy 3Morning Sickness or NVP: National Survey of Nurse Practitioners Points to Underreporting of Common Condition in Pregnancy 4Morning Sickness or NVP: National Survey of Nurse Practitioners Points to Underreporting of Common Condition in Pregnancy 5
(Date:9/18/2014)... Why is it that when people are too stressed ... Researchers from the Brain Mind Institute (BMI) at EPFL ... the relationship between chronic stress and the loss of ... an enzyme attacks a synaptic regulatory molecule in the ... Nature Communications . , Carmen Sandi,s team ...
(Date:9/18/2014)... ultimate form of camouflage: you don,t just blend in, ... not as uncommon as you might think. Kathryn Feller, ... that the larval life stages of many marine species ... anatomy that most creatures cannot make transparent. Feller explains ... each individual eye unit with an opaque pigment to ...
(Date:9/18/2014)... nestling in the protective tentacles of host anemones, but ... hundreds of kilometres across the open ocean. Although the ... predicted, this is the first time that the high ... observed. , Dr Steve Simpson, Senior Lecturer in Marine ... and colleagues from the Australian Research Council Centre of ...
Breaking Biology News(10 mins):How stress tears us apart 2Transparent larvae hide opaque eyes behind reflections 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3
... featured in the October 2008 Journal of the ... Restraint and Gestational Weight Gain, Learner-Centered Nutrition Education ... Low-Income Women of Childbearing Age, Changes in Nutrient ... 2 Diabetes Following a Low-Fat Vegan Diet or ...
... Metcalf and his collaborators have developed a way to ... malaria less expensive. Metcalf set out ... known as phosphonates, is made in nature by bacteria. ... phosphonates have antibiotic properties. Recently, Metcalf and his lab ...
... global scientific community will gather in Maputo, Mozambique, 21-24 ... International Council for Science (ICSU)the first time an ICSU ... than 250 leading scientists from around the world will ... address how science can contribute to solving some of ...
Cached Biology News:News from the October 2008 Journal of the American Dietetic Association 2New way to make malaria medicine also first step in finding new antibiotics 2New way to make malaria medicine also first step in finding new antibiotics 3New way to make malaria medicine also first step in finding new antibiotics 4Global science community to gather in Mozambique 2
Proliferin (N-14)...
... the computing power of your ValveBank system! ... a PC computer running Windows 98, 2000, XP ... programs to disk, print out program listings, then ... one simple step., EasyCode is used for programming ...
...
... formation of phosphodiester bonds in the presence ... hydroxyl and 5' phosphate termini. The unique ... can be performed in 5 minutes (1). ... this enzyme. A T4 DNA Ligase ...
Biology Products: